Evaluation of sCD30 level in maternal serum in pregnancies complicated by severe preeclampsia

Med Wieku Rozwoj. 2011 Jan-Mar;15(1):73-8.

Abstract

Background: Our study was a continuation of the research on the immunological pathology and changes associated with pregnancy complicated by preeclampsia. The aim of this study was to compare the levels of soluble CD30 in maternal serum in the group of women with preeclamptic pregnancy and in the control group of normotensive healthy pregnant women.

Material and methods: The study was carried out in 50 patients with pregnancies complicated bysevere preeclampsia (Pre group). The control group consisted of 34 healthy normotensive pregnant patients with singleton uncomplicated pregnancies (group K). Maternal serum soluble CD30 concentrations were estimated using a sandwich ELISA assay. There were no statistically significant differences in gravidity, parity, maternal age, body height and BMI in patient profiles between groups. Maternal weight was lower in the control group of patients than in the group of preeclamptic patients. Systolic and diastolic blood pressure and mean arterial blood pressure were higher in the study group ofpreeclamptic pregnant women than in the control group.

Results: The levels of maternal serum soluble CD30 in preeclamptic women did not differ in comparison with healthy controls. The mean values were 21.257+/-10.304 ng/mL in the Pre group compared with 21.806+/-11.076 ng/mL in the control group.

Conclusions: Since preeclampsia is not associated with a fall of the maternal soluble CD30 level it can not constitute a measure of improving diagnostic and therapeutic management.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Ki-1 Antigen / blood*
  • Poland
  • Pre-Eclampsia / immunology*
  • Predictive Value of Tests
  • Pregnancy
  • Prenatal Care / methods
  • Reference Values
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Young Adult

Substances

  • Biomarkers
  • Ki-1 Antigen